Alcohol Use Disorder Pipeline Insight, 2026 Examines 25+ Companies and 25+ Emerging Therapies
Dublin, Sept. 11, 2026 (GLOBE NEWSWIRE) -- "Alcohol Use Disorder - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.
The "Alcohol Use Disorder - Pipeline Insight, 2026" report delivers a comprehensive analysis of the global Alcohol Use Disorder pipeline, covering more than 25 companies and 25 investigational drugs. The report evaluates clinical and nonclinical candidates, including products in Phase III, Phase II, Phase I, preclinical and discovery-stage development. It also reviews discontinued and inactive Alcohol Use Disorder pipeline products.
Alcohol Use Disorder is a heterogeneous condition influenced by genetic, neurobiological and environmental factors. Research indicates that approximately half of the associated risk may be heritable, while environmental exposure and gene-environment interactions contribute substantially to disease development. Alcohol affects multiple neurotransmitter systems involved in reward, motivation, stress and behavioral reinforcement, including dopamine, glutamate, gamma-aminobutyric acid, serotonin, corticotropin-releasing factor and endogenous opioid pathways.
The Alcohol Use Disorder pipeline report provides detailed commercial and clinical assessments of emerging therapies. Each pipeline drug profile may include its mechanism of action, clinical trial activity, regulatory status, development technology, licensing agreements, collaborations, funding, designations, mergers and acquisitions, and other product-related developments. Treatment guidelines, unmet medical needs and the potential impact of new therapies are also examined.
Alcohol Use Disorder Pipeline Highlights
Pharmaceutical companies, biotechnology organizations and academic institutions are investigating novel approaches intended to reduce harmful alcohol consumption, support abstinence and improve treatment adherence. Development strategies include genetically targeted therapies, receptor-directed compounds, long-acting formulations and candidates designed to regulate neural pathways associated with alcohol craving and reinforcement.
The report assesses Alcohol Use Disorder drugs by development stage, route of administration, molecule type and product category. Routes of administration covered include oral, intravenous, subcutaneous, parenteral and topical delivery. Molecule categories include small molecules, peptides, monoclonal antibodies, recombinant fusion proteins, polymers and gene therapies. Products are also classified as monotherapies, combination therapies or candidates with potential use in both settings.
Selected Emerging Alcohol Use Disorder Drugs
AD04 - Adial Pharmaceuticals: AD04 is a genetically targeted investigational therapy being developed for Alcohol Use Disorder. The candidate is intended for patients with specific genetic markers identified through a proprietary companion diagnostic test. Its activity is associated with modulation of serotonergic and dopaminergic pathways involved in alcohol-related reward and reinforcement. Phase III findings have indicated potential reductions in heavy drinking days among a genetically defined patient subgroup.
Sunobinop - Imbrium Therapeutics: Sunobinop is an investigational oral compound designed to activate the nociceptin/orphanin FQ peptide receptor. This receptor is expressed across the central and peripheral nervous systems and is associated with several biological processes relevant to addiction and behavioral regulation. Sunobinop is currently being evaluated in Phase II clinical development for Alcohol Use Disorder.
BICX104 - BioCorRx Pharmaceuticals: BICX104 is a biodegradable, long-acting subcutaneous naltrexone pellet designed to improve treatment adherence compared with shorter-duration formulations. In a Phase I study involving healthy volunteers, the candidate was reported to be well tolerated, with no serious adverse events, and maintained therapeutic naltrexone plasma concentrations for 84 days. BICX104 is in Phase I development for Alcohol Use Disorder.
Pipeline Development and Competitive Landscape
Approximately 25 companies are advancing therapies across the Alcohol Use Disorder clinical pipeline. Adial Pharmaceuticals is among the companies with a candidate in Phase III development. The report also evaluates mid-stage, early-stage, preclinical and discovery programs, providing insight into clinical study design, pharmacological activity, development status and recent corporate announcements.
Key companies covered in the Alcohol Use Disorder pipeline analysis include:
Selected pipeline products include:
Strategic Insights Covered in the Report
The "Alcohol Use Disorder - Pipeline Insight, 2026" report analyzes industry-industry and industry-academic collaborations, licensing agreements, acquisitions, mergers and funding activity. It also examines emerging drug classes, clinical trial progress, regulatory designations and technologies designed to address limitations associated with existing Alcohol Use Disorder treatments.
Key report assessments include Alcohol Use Disorder pipeline analysis, therapeutic profiling, clinical-stage segmentation, inactive drug evaluation, unmet needs and the prospective impact of emerging treatments. The report also addresses the number of companies active in the field, the distribution of candidates by development phase, recent clinical study activity and the strategic partnerships influencing Alcohol Use Disorder research and development.
By combining scientific, clinical and commercial intelligence, the report provides pharmaceutical companies, investors, healthcare stakeholders and research organizations with a structured view of the evolving Alcohol Use Disorder treatment landscape and the opportunities expected to shape future pipeline development.
Key Topics Covered:
Introduction
Executive Summary
Alcohol Use Disorder: Overview
Pipeline Therapeutics
Therapeutic Assessment
Alcohol Use Disorder- Analytical Perspective
Late Stage Products (Phase III)
AD04: Adial Pharmaceuticals
Mid Stage Products (Phase II)
Sunobinop: Imbrium Therapeutics
Early Stage Products (Phase I)
BICX104: BiocorRx Pharmaceuticals
Preclinical and Discovery Stage Products
Drug name: Company name
Inactive Products
Alcohol Use Disorder Key Companies
Alcohol Use Disorder Key Products
Alcohol Use Disorder- Unmet Needs
Alcohol Use Disorder- Market Drivers and Barriers
Alcohol Use Disorder- Future Perspectives and Conclusion
Alcohol Use Disorder Analyst Views
Alcohol Use Disorder Key Companies
Appendix
List of Tables
Table 1 Total Products for Alcohol Use Disorder
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Alcohol Use Disorder
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/h6dfod
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.